Sheets Smith Investment Management Buys New Position in Kiniksa Pharmaceuticals International, plc $KNSA

Sheets Smith Investment Management purchased a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 16,992 shares of the company’s stock, valued at approximately $660,000.

A number of other hedge funds and other institutional investors have also modified their holdings of KNSA. US Bancorp DE purchased a new position in shares of Kiniksa Pharmaceuticals International during the first quarter valued at approximately $33,000. Vanguard Group Inc. raised its holdings in Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after acquiring an additional 151,604 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Kiniksa Pharmaceuticals International by 34.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 164,372 shares of the company’s stock worth $3,651,000 after purchasing an additional 42,353 shares during the period. Invesco Ltd. boosted its holdings in shares of Kiniksa Pharmaceuticals International by 137.4% during the first quarter. Invesco Ltd. now owns 33,492 shares of the company’s stock worth $744,000 after purchasing an additional 19,384 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $16,992,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KNSA has been the topic of a number of research analyst reports. The Goldman Sachs Group raised their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a report on Thursday, September 25th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Citigroup increased their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $52.00.

Insider Activity

In related news, CEO Sanj K. Patel sold 97,390 shares of the stock in a transaction on Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total value of $3,781,653.70. Following the completion of the sale, the chief executive officer directly owned 111,794 shares in the company, valued at approximately $4,340,961.02. This represents a 46.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Paolini sold 82,542 shares of the business’s stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $37.14, for a total value of $3,065,609.88. Following the transaction, the insider owned 61,324 shares in the company, valued at approximately $2,277,573.36. This represents a 57.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 553,057 shares of company stock worth $21,582,372 in the last quarter. Insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $42.00 on Friday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $42.98. The firm has a 50 day moving average price of $40.11 and a 200 day moving average price of $34.84. The company has a market cap of $3.18 billion, a PE ratio of 93.34 and a beta of 0.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business had revenue of $180.86 million for the quarter, compared to analysts’ expectations of $166.64 million. During the same quarter in the prior year, the firm earned ($0.18) earnings per share. Kiniksa Pharmaceuticals International’s quarterly revenue was up 61.2% compared to the same quarter last year. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.